Introduction
Small cell lung cancer (SCLC), which accounts for 15% of all the lung cancers, is an extremely aggressive disease with particularly poor survival rates. 1 Most often, the SCLC patients are categorized into the limited-stage disease (LD) or extensive-stage disease (ED) according to the Veterans Administration Lung Study Group (VALSG) staging system. Furthermore, rapid doubling time and early onset dissemination are the main characteristics of SCLC. SCLC is also characterized by initial chemosensitivity, and the first-line treatment of choice is the platinum-based regimen, usually cisplatin and etoposide. 2, 3 However, despite initial high response rates to chemotherapy, SCLC inevitably relapses. The follow-up treatment for relapsed SCLC is still a challenge. Currently, target therapies and immunotherapeutic agents are under clinical investigation. 4, 5 However, most of them have limited efficacy, and till now, there is no efficient drug approved for SCLC. 6 Thus, discovering novel predictive biomarkers to differentiate subtypes of SCLC for personalized treatments is the urgent need.
Epidermal growth factor receptor (EGFR) is a transmembrane protein that is a receptor for members of the EGF family of extracellular protein ligands. When endogenous ligands, such as EGF, bind to EGFR, receptor homodimerization or submit your manuscript | www.dovepress.com
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lu et al heterodimerization occurs at the cell surface and eventually leads to internalization of the dimerized receptor. 7 After receptor dimerization, the autophosphorylation of the intracytoplasmic EGFR tyrosine kinase domain will happen to stimulate the intracellular signal transduction cascade through several downstream pathways. 8 The mutations in EGFR exons 18, 19 , and 21 in NSCLC are correlated to the response of tumors to tyrosine kinase inhibitors (TKIs). More concretely, short in-frame deletions in exon 19 and a specific point mutation in exon 21 at codon 858 are the most common EGFR mutations in NSCLC patients and correlated with the sensitive response of small-molecule EGFR-TKI. 3, 4 Whereas the T790M gatekeeper point mutation at exon 20, accounting for ~50% of all cases, is reported to be the most frequently observed resistance mechanism. 9 Kirsten rat sarcoma viral oncogene (KRAS) is a GTP-binding protein, involved in G-protein-coupled receptor signaling. The mutation status of the KRAS gene predicts the therapeutic efficacy of EGFR-TKIs in NSCLC. The patients with the wild-type KRAS gene may benefit from the TKI therapy. 10 v-raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase links the RAS GTPase to the downstream signaling pathway of KRAS to phosphorylate the MEK protein directly. The mutations in the BRAF gene increase the kinase activity and, in turn, the constitutive stimulation of MAPK2 and MAPK3. The rate of mutation in the BRAF gene in NSCLC is relatively low. BRAF mutations could predict the effect of MEK inhibitors on NSCLC cells. 11 Phosphatase and tensin homolog (PTEN) regulates several physiological processes by inhibiting the phosphoinositide 3-kinase-v-akt murine thymoma viral oncogene homolog-mammalian target of rapamycin pathway (PI3K/AKT/mTOR pathway) through its lipid phosphatase activity. Shibata et al showed that the mutation in phosphatidylinositol-3-kinase catalytic α (PIK3CA) in SCLC cells renders them more sensitive to tricribine than the cells with the wild-type gene. Moreover, the SCLC cells harboring a cisplatin-resistant subclone of PIK3CA mutant were sensitive to tricribine similar to those without the resistance. 12, 13 Another study reported one adenocarcinoma patient with an L858R mutation in EGFR who displayed a robust response to erlotinib (first line of drug). The largest nodule progressed after 1 year. The core biopsy of this lesion revealed a histological transformation to SCLC that carried the L858R mutation in EGFR and acquired a PIK3CA mutation that disappeared after 6 months. Subsequently, the patient with the histological transformation to adenocarcinoma responded to a repeat course of erlotinib as the second-line course treatment. 14 Le et al revealed a lack of response to EGFR TKIs in EGFR-mutated de novo SCLC and large cell neuroendocrine carcinomas. 15 Therefore, elucidating the mutations in EGFR, KRAS, BRAF, PTEN, and PIK3CA in SCLC is imperative.
Two prospective studies from Taiwan and Japan reported 2.6% and 4% EGFR mutations, respectively. 16, 17 Surgery can be used in SCLC patients with T1-2N0M0, which is ,5% of all the SCLC patients. Thus, obtaining tumors for the detection of EGFR mutation in SCLC patients is rather challenging. 18 High-resolution melting (HRM) is a precise method, with 92% sensitivity and 100% specificity, for detecting the EGFR mutation using formalin-fixed tissues. This approach is also useful in predicting the clinical outcomes of NSCLC patients treated with gefitinib. 19 Thus, the simplicity, promptness, high sensitivity, and low rate of false-positive mutation in the HRM analysis renders it to be an optimal approach for detecting the EGFR mutations in circulating DNA of lung cancer patients. 20, 21 In order to distinguish the mutation status of EGFR, KRAS, BRAF, PTEN, and PIK3CA in SCLC patients, we used the HRM technology to assess the genes in the plasma samples.
Materials and methods Patients
From August 2012 to December 2015, 99 SCLC patients (10 females and 89 males) were prospectively assimilated in this study from the Zhejiang Cancer Hospital, People's Republic of China. The pathological diagnosis comprising of 98 conventional SCLC and 1 combined SCLC was based on the standard criteria defined by World Health Organization Classification. The mean age of patients was 60 years (range, 24-79 years). The stages as per the VALSG were as follows: LD in 44 patients and ED in 55 patients. These encompassed 14 patients who were nonsmokers, 1 patient was light, 3 were moderate, and 81 were heavy smokers. The mean pack-years was 46 (range, 0-150). The characteristics of 99 SCLC patients are summarized in Table 1 . The study was approved by the Medical Ethical Committee of Zhejiang Cancer Hospital, and the patients signed the informed consent.
Detection of gene mutation using hrM
A total of 99 blood samples were included in this study for assessing EGFR, KRAS, BRAF, PTEN, PIK3CA mutations. Five milliliters of vascular blood samples was withdrawn in EDTA-anticoagulation tubes. The plasma was isolated from blood samples by centrifugation at 4,000 rpm for 10 min. Then, DNA was extracted from the plasma samples using the High Pure PCR Template Preparation Kit (Roche, Mannheim, Germany) according to the manufacturer's protocol. Human (Table 2) .
EVA-Green (Biotium, Fremont, CA, USA) was used as the intercalating dye. The reaction mixture consisted of 5 ng plasma DNA, 10× PCR buffer, 2.5 mM MgCl 2 , 0.5 µM of each primer, 200 µM dNTP, 1U of FastStart Taq polymerase (Roche), and PCR grade water in a volume of 20 µL.
PCR cycling and HRM analysis were performed on the LightCycler ® 480 Real-Time PCR System (Roche 
Results
By HRM, blood samples from 99 SCLC patients were sequenced to detect the genetic mutation of target genes (EGFR, KRAS, BRAF, PIK3CA, and PTEN). Consequently, target-site mutation was detected in 15 patients. Among them, these mutations of 12 patients were mutually exclusive, and the remaining 3 patients carried multiple mutations.
As shown in Table 3 , the number of patients who carried EGFR/KRAS/BRAF/PIK3CA/PTEN mutation was 9/5/1/1/0, respectively. In detail, EGFR 18 (G719X) mutation in 5 (5.05%) patients, EGFR 19 (del) mutation in 2 (2.02%) patients, EGFR 20 (T790M) mutation in 3 (3.03%) patients, EGFR 21 (L858R) mutation in 2 (2.02%) patients, KRAS 2 (G13D) mutation in 5 (5.05%) patients, BRAF 15 (V600E) mutation in 1 (1.01%) patient (Figure 1 ), PIK3CA 9 (E542K) mutation in 1 (1.01%) patient (Figure 2) , and no mutations of PTEN 5 (R130G), PTEN 6 (R173C), PTEN 8 (T319fs*1), and PIK3CA 20 (H1047R) were found. Three patients with multiple mutations, one patient harboring EGFR 18 (G719X)
and EGFR 19 (del) mutations (Figure 3) , one patient harboring EGFR 20 (T790M) and EGFR 21 (L858R) (Figure 4) , and another patient harboring EGFR 18 (G719X), EGFR 20 (T790M), and KRAS 2 (G13D) mutations ( Figure 5 ) were identified. The nine patients (one female and eight males) harboring EGFR mutations expressed a mean age of 59 years (range, 48-71 years). The stages were as follows: LD in four patients and ED in five patients. One patient was a nonsmoker, and eight were heavy smokers.
Discussion
In the present study, the percentage of EGFR mutations in SCLC plasma is higher than from the tumor tissue in previous reports. [16] [17] [18] 22 The EGFR mutation from tumor tissue can only reflect the mutation status of the tissue that is evaluated; heterogeneity occurs widely in different parts of the tissue in the same patient. 23 The EGFR mutation in plasma may originate from all the tumor tissues of the whole body. The patients with EGFR-mutated SCLC tended to be females, nonsmokers, and in SCLC including "conventional SCLC and combined SCLC". Combined SCLC is SCLC containing discrete areas of non-mall cell morphologic components. [25] [26] [27] A study revealed 28% of the SCLC patients who underwent surgical resection exhibited combined SCLC, 28 while other reports demonstrated that combined SCLC accounted for 1%-3.2% of all the SCLC cases who received no surgery. 29, 30 Surgery can be considered only in T1-2N0M0 SCLC patients; 
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EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in sclc however, these cases have been reported to account for ,5% of all the SCLC patients. 18 None of our SCLC patients underwent surgery. The diagnosis of combined SCLC using biopsy or needle puncture is extremely arduous. Twenty to thirty percent of our SCLC patients may have combined SCLC, and we could not diagnose combined SCLC through small specimens obtained from biopsy or needle puncture. Heterogeneity can also explain the double mutation of EGFR in plasma of the same patient. SCLC developing in association with adenocarcinoma, either synchronously or metachronously, seemed to correlate with the EGFR mutation, irrespective of TKI usage. 31 The EGFR mutation may easily occur in SCLC combined adenocarcinoma than in SCLC combined with other NSCLC complements. 25 Because of the specific involvement of EGFR mutations in adenocarcinoma, it is suggested that the SCLCs may have developed from preexisting adenocarcinomas. 17 As we all know, EGFR activating mutations, including exon 19 deletions or an exon 21 Leu858Arg mutation, present favorable outcome after treating with EGFR TKI. 32, 33 In SCLC, several studies have also performed a similar research. A 72-year-old woman with EGFR exon 19 mutation (del E746-A750) utilized gefitinib as the treatment method. 34 After 3 weeks, CT was performed, which revealed marked regression of both the primary lung tumor and the metastatic liver tumor. The histological examination of this patient was confirmed as SCLC. Another clinical report also revealed a pronounced positive effect of gefitinib in a patient with metastatic SCLC. 35 Secondgeneration inhibitors, including afatinib, dacomitinib, and neratinib, have been verified markedly with high efficacy in NSCLC patients with the G719X mutation. 36, 37 Based on our research, EGFR 18 (G719X) is the most common EGFR mutation of SCLC in the current report, which is different from lung adenocarcinoma with the main mutations EGFR 19 (del) and EGFR 21 (L858R).
38,39 Thus, we speculated that G719X might be a promising mutation for treatment. Bordi et al reported that all the SCLC cases harbored wild-type BRAF, KRAS, platelet-derived growth factor receptor alpha, and c-KIT (data available for 82 patients) genes. 24 Other studies reveal ~2%-5% KRAS mutations in patients with SCLC. 40, 41 Our study also confirmed that fewer mutations of KRAS and BRAF in SCLC patients might be correlated with 
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EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in sclc the resistance to TKI in NSCLC in the background of these mutations. 10, [42] [43] [44] [45] In our study, EGFR and KRAS mutations are detected in one SCLC patient. Le et al demonstrated the lack of response to EGFR TKIs in one EGFR-mutated de novo SCLC patient, which might be attributed to the KRAS or BRAF mutation; however, the underlying mechanism is yet to be elucidated. 15 Selumetinib is a tight-binding, noncompetitive inhibitor of MEK 1 and 2 that acts downstream of KRAS and is administered orally. Recently, a randomized, Phase II trial involving selumetinib plus docetaxel improved the progression-free survival when compared with docetaxel alone in patients who were treated previously for advanced NSCLC harboring the KRAS mutant. 46 Furthermore, the role of BRAF mutation in NSCLC and the optimal treatment are yet to be elucidated. The regression of intracranial disease by Robinson et al indicated that vemurafenib traversed the blood-brain barrier and efficaciously treated the brain metastasis in lung cancer patients with a V600E mutation in BRAF gene. 47 Thus, selumetinib and vemurafenib in SCLC with KRAS or BRAF mutation can be explored prospectively.
The PI3K/AKT/mTOR pathway plays a unique role with respect to genomic alterations in SCLC. 48 The inactivated PTEN advances the SCLC in a genetic mouse model, thereby suggesting that a subset of patients with SCLC can be treated by targeting the PTEN pathway. 49 Li et al indicated that adenovirus-mediated PTEN together with cisplatin could be an efficient novel therapeutic modality for the treatment of patients with SCLC. 50 Tricribine is a small molecule inhibitor of AKT signaling. It is localized downstream of PIK3CA and inhibited the growth and colony formation of "PIK3CA-addicted" cells significantly. Moreover, the SCLC cells harboring the mutated PIK3CA are more sensitive to tricribine than the wild-type cells. On the other hand, the cisplatin-resistant subclones of PIK3CA-mutant SCLC cells exhibited sensitivity to tricribine similar to those with PIK3CA. The anti-AKT molecular therapy was found to be efficient for a subgroup of SCLC with PIK3CA mutation. 51 PF-4989216 is a potential cancer therapeutic candidate for the treatment of SCLC patients with PIK3CA mutation and without PTEN loss. 52 Reverse transcription-polymerase chain reaction and direct sequencing technology were employed for the detection of PIK3CA mutation in 14 cases of patients with SCLC, assimilated retrospectively, who underwent surgical treatment at the Zhejiang Cancer Hospital from 2002 to 2010. The analysis did not reveal any mutations in exons 9 and 20 of the PIK3CA gene in the tumor tissue of patients with SCLC. 53 In the current study, one patient presented the PIK3CA mutation. The percentage of PIK3CA mutations is similar to PTEN: ~5%.
27,40, 48 Sasaki et al and Schmid et al 43, 54 established the synergistic effects of the combination therapy of Erlotinib and RAD001 with respect to cell viability, proliferation, and autophagy.
Conclusion
Our study revealed the mutation of the targeted genes from SCLC. The mutations in KRAS, BRAF, and PIK3CA are rare in patients with SCLC, and the mutation in EGFR might differ from that in lung adenocarcinoma. The experimental results laid the foundation for better understanding of the mutation characteristics of SCLC and the following research on the application of targeted drugs.
